Last reviewed · How we verify
NCT05100420: HiRO-HCM
Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository
trial in Hypertrophic Cardiomyopathy in 2,000 participants. Enrolling by invitation.
23 February 2026
Quick facts
| Lead sponsor | Montreal Heart Institute |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 23 February 2021 |
| Primary completion | 23 February 2026 |
| Estimated completion | 23 August 2027 |
| Sites | 13 locations across Canada |
Conditions studied
- Hypertrophic Cardiomyopathy — all drugs for Hypertrophic Cardiomyopathy →
- Hypertrophic Obstructive Cardiomyopathy — all drugs for Hypertrophic Obstructive Cardiomyopathy →
- Familial Hypertrophic Cardiomyopathy — all drugs for Familial Hypertrophic Cardiomyopathy →
- Cardiomyopathies — all drugs for Cardiomyopathies →
Sponsor
Montreal Heart Institute
Who can join
Eligibility, any sex, with Hypertrophic Cardiomyopathy or Hypertrophic Obstructive Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD). The HiRO Hypertrophic Cardiomyopathy registry, biobank and imaging data repository (HiRO-HCM) is a multicenter study that will prospectively enroll patients with HCM as well as those carrying sarcomeric gene variants predisposing to HCM. The objectives of HiRO-HCM are: 1. to better understand the natural history of the disease and identify clinical markers and biomarkers for adverse outcomes; 2. to derive and validate risk prediction models for disease expression, complications and response to therapy; 3. to better define the genetic architecture of sarcomeric and non-sarcomeric HCM.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05100420
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertrophic Cardiomyopathy
Currently open trials in the same condition.
- NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
- NCT06490250 — Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients · NA · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06549608 — A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada · active not recruiting
- NCT05939700 — Mavacamten Pregnancy Surveillance Program · recruiting
Other Montreal Heart Institute trials
Trials by the same sponsor.
- NCT07524335 — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial · Phase 3 · not yet recruiting
- NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
- NCT07391358 — DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid · NA · not yet recruiting
- NCT05450328 — Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation · Phase 2 · not yet recruiting
- NCT07144722 — Prehabilitation Program for Patients Awaiting Elective Heart Surgery at Increased Risk of Postoperative Complications: F · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05100420 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Montreal Heart Institute
- Last refreshed: 30 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05100420.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing